Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase
- PMID: 32447145
- DOI: 10.1016/j.cmpb.2020.105494
Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase
Abstract
Background and Objectives The Dual-specificity tyrosine-phosphorylation regulated kinase-1A (DYRK1A) a serine/threonine kinase that has freshly gained recognition as an essential drug target due to the discovery of its involvement in pathological diseases. The development of new potent inhibitors of DYRK1A would contribute to clarify the molecular mechanisms of associated diseases. It would administer a new lead compound for molecular-targeted protein, which was the primary focus of our study. Methods The library of in-house synthesized pyrrolone-fused benzosuberene (PBS) compounds was docked with DYRK1A receptor. Further, molecular mechanics-Poisson Boltzmann surface area (MM-PBSA) estimations were conducted to confirm our docking outcomes and compared the stability of chosen complexes with the 2C3 (standard molecule) complex. Results This study reports Ligand15, Ligand14, and Ligand11 as potent inhibitors which showed higher ligand efficiency, binding affinity, lipophilic ligand efficiency, and favorable torsion values as compared to 2C3. Conclusion The stated methodologies revealed a unique mechanism of active site binding. The binding interactions within the active site showed that the chosen molecules had notable interactions than the standard molecule, which led to the generation of potential compounds to inhibit DYRK1A.
Keywords: DYRK1A; LE; LLE; MD-simulations; MM-PBSA.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no conflicts to disclose.
Similar articles
-
Mechanism of dual specificity kinase activity of DYRK1A.FEBS J. 2013 Sep;280(18):4495-511. doi: 10.1111/febs.12411. Epub 2013 Jul 22. FEBS J. 2013. PMID: 23809146
-
Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.Molecules. 2022 Feb 9;27(4):1159. doi: 10.3390/molecules27041159. Molecules. 2022. PMID: 35208955 Free PMC article.
-
Discovery of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors using an artificial intelligence model and their effects on tau and tubulin dynamics.Biomed Pharmacother. 2024 Dec;181:117688. doi: 10.1016/j.biopha.2024.117688. Epub 2024 Nov 25. Biomed Pharmacother. 2024. PMID: 39591664
-
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. doi: 10.1080/13543776.2017.1360285. Epub 2017 Aug 2. Expert Opin Ther Pat. 2017. PMID: 28766366 Review.
-
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.J Med Chem. 2018 Nov 21;61(22):9791-9810. doi: 10.1021/acs.jmedchem.8b00185. Epub 2018 Jul 20. J Med Chem. 2018. PMID: 29985601 Review.
Cited by
-
Novel benzylidene benzofuranone analogues as potential anticancer agents: design, synthesis and in vitro evaluation based on CDK2 inhibition assays.3 Biotech. 2022 Oct;12(10):256. doi: 10.1007/s13205-022-03312-1. Epub 2022 Sep 2. 3 Biotech. 2022. PMID: 36065423 Free PMC article.
-
Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.3 Biotech. 2022 Dec;12(12):343. doi: 10.1007/s13205-022-03407-9. Epub 2022 Nov 6. 3 Biotech. 2022. PMID: 36353445 Free PMC article.
-
In Silico Analysis of Neutralizing Antibody Epitopes on The Hepatitis C Virus Surface Glycoproteins.Cell J. 2023 Jan 1;25(1):62-72. doi: 10.22074/cellj.2022.253363. Cell J. 2023. PMID: 36680485 Free PMC article.
-
A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2.Comput Biol Med. 2021 Aug;135:104555. doi: 10.1016/j.compbiomed.2021.104555. Epub 2021 Jun 8. Comput Biol Med. 2021. PMID: 34144270 Free PMC article.
-
In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2.Molecules. 2021 Sep 21;26(18):5724. doi: 10.3390/molecules26185724. Molecules. 2021. PMID: 34577194 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources